NLRP3 and lymphoma: Though the investigation of NLRP3 inflammasome therapeutic targeting in the setting of lymphoma is still at a premature stage, its activity could be modulated by multiple approaches: (a) the abrogation of upstream signaling pathways, (b) the direct inhibition of its components, and (c) the antagonism of its end-products.